Spinal Cord Injury Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

Spinal Cord Injury Overview

Spinal cord injury is defined as traumatic damage to the spinal cord or nerves at the end of the spinal canal. This affects the conduction of sensory and motor signals across the site of the lesion. Spinal cord injury is a debilitating neurological condition with tremendous socioeconomic impact on affected individuals and the health care system.

“Spinal Cord Injury Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Spinal Cord Injury Market.

The Spinal Cord Injury Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Spinal Cord Injury Pipeline Report:

• Companies across the globe are diligently working toward developing novel Spinal Cord Injury treatment therapies with a considerable amount of success over the years. Spinal Cord Injury Key players such as – Athersys, Kancera, AlaMab therapeutics, ReNetX Bio, Histocell, Lineage Cell Therapeutics, AbbVie, Mitsubishi Tanabe Pharma, Pharmazz, Eusol Biotech, KringlePharma, and others, are developing therapies for the Spinal Cord Injury treatment 
• Spinal Cord Injury Emerging therapies such as – Allogeneic stem cell therapy, KAND 567, ALMB0166, AXER-204, FAB117-HC, AST-OPC1, Elezanumab, MT 3921, PMZ-1620, ES 135, KP-100IT, and others are expected to have a significant impact on the Spinal Cord Injury market in the coming years.   
• In July 2020, Kringle Pharma initiated a non-randomized, multicenter, and confirmatory study by intrathecal administration of KP-100IT in subjects with Acute Spinal Cord Injury

Route of Administration

Spinal Cord Injury pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical
• Molecule Type

Molecule Type

Products have been categorized under various Molecule types, such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Spinal Cord Injury Pipeline Therapeutics Assessment

• Spinal Cord Injury Assessment by Product Type
• Spinal Cord Injury By Stage and Product Type
• Spinal Cord Injury Assessment by Route of Administration
• Spinal Cord Injury By Stage and Route of Administration
• Spinal Cord Injury Assessment by Molecule Type
• Spinal Cord Injury by Stage and Molecule Type

DelveInsight’s Spinal Cord Injury Report covers around 35+ products under different phases of clinical development like-

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Some of the key companies in the Spinal Cord Injury Therapeutics Market include:

Key companies developing therapies for Spinal Cord Injury are – Athersys, Kancera, AlaMab therapeutics, ReNetX Bio, Histocell, Lineage Cell Therapeutics, Eli Lilly and Company, Ferrer Internacional S.A, AbbVie, Mitsubishi Tanabe Pharma, Pharmazz, Eusol Biotech, Kringle Pharma, and others.

Emerging Spinal Cord Injury Drugs Under Different Phases of Clinical Development Include:

• KAND 567: Kancera
• ALMB0166: AlaMab therapeutics
• AXER-204: ReNetX Bio
• FAB117-HC: Histocell
• AST-OPC1: Lineage Cell Therapeutics
• Elezanumab: AbbVie
• MT 3921: Mitsubishi Tanabe Pharma
• PMZ-1620: Pharmazz
• ES 135: Eusol Biotech
• KP-100IT: KringlePharma
• MT-3921: Mitsubishi Tanabe Pharma Corporation

• Allogeneic stem cell therapy: Athersys

Get a Free Sample PDF Report to know more about Spinal Cord Injury Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/spinal-cord-injury-pipeline-insight

Spinal Cord Injury Pipeline Analysis:

The Spinal Cord Injury pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Spinal Cord Injury with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Spinal Cord Injury Treatment.
• Spinal Cord Injury key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Spinal Cord Injury Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Spinal Cord Injury market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Spinal Cord Injury product details are provided in the report. Download the Spinal Cord Injury pipeline report to learn more about the emerging Spinal Cord Injury therapies

Spinal Cord Injury Pipeline Market Drivers

• Increase in prevalence of spinal cord injury 
• Increasing awareness about the spinal cord injury

Spinal Cord Injury Pipeline Market Barriers

• Absence of essential emergency and acute care 
• Lack of importance of a systematic approach towards the management of Spinal cord Injury 

Scope of Spinal Cord Injury Pipeline Drug Insight    

• Coverage: Global
• Key Spinal Cord Injury Companies: Athersys, Kancera, AlaMab therapeutics, ReNetX Bio, Histocell, Lineage Cell Therapeutics, AbbVie, Mitsubishi Tanabe Pharma, Pharmazz, Eusol Biotech, KringlePharma, and others
• Key Spinal Cord Injury Therapies: Allogeneic stem cell therapy, KAND 567, ALMB0166, AXER-204, FAB117-HC, AST-OPC1, Elezanumab, MT 3921, PMZ-1620, ES 135, KP-100IT, and others
• Spinal Cord Injury Therapeutic Assessment: Spinal Cord Injury current marketed and Spinal Cord Injury emerging therapies
• Spinal Cord Injury Market Dynamics: Spinal Cord Injury market drivers and Spinal Cord Injury market barriers 

Request for Sample PDF Report for Spinal Cord Injury Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report to know more about Spinal Cord Injury drugs and therapies

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services